A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

This study is evaluating the safety and tolerability of an investigational drug called ALN-APP — a gene-silencing therapy designed to reduce levels of amyloid precursor protein (APP) in the brain — in patients with early-onset Alzheimer's disease (EOAD), which affects people before age 65. **You may be eligible if...** - You have mild cognitive impairment or mild dementia believed to be caused by early-onset Alzheimer's disease - Your CDR (Clinical Dementia Rating) score is 0.5 or 1.0 (mild impairment) and MMSE score is above 20 - You meet biological criteria for Alzheimer's disease (e.g., biomarker confirmation) **You may NOT be eligible if...** - Your dementia is caused by something other than Alzheimer's disease - You have abnormal liver enzyme levels - You have significantly reduced kidney function - You are taking certain medications that could interact with the study drug Talk to your doctor to see if this trial is right for you.